Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: Aberrant triggering of a patient's T cells

Haematologica

Volumn 95, Issue 4, 2010, Pages 627-636

  Hellqvist, Eva ^a   Kvarnström, Maria ^a   Söderberg, Anita ^a   Vrethem, Magnus ^a   Ernerudh, Jan ^a   Rosén, Anders ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

CD5+ B cells; MGUS; Monoclonal gammopathy of undetermined significance; Myelin P0; Peripheral neuropathy

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 2; MYELIN PROTEIN;

AGED; ARTICLE; B LYMPHOCYTE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; MONOCLONAL IMMUNOGLOBULINEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; PROTEIN PROCESSING; T LYMPHOCYTE ACTIVATION;

AGED; ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN M; INTERFERON-GAMMA; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MYELIN P0 PROTEIN; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTORS, ANTIGEN, B-CELL; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 77950647497     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.015123     Document Type: Article

References (61)

1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-9.
2. Martín-Jiménez P, García-Sanz R, Balanzategui A, Alcoceba M, Ocio E, Sanchez ML, et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica. 2007;92(5):635-42.
3. Sahota SS, Forconi F, Ottensmeier CH, Provan D, Oscier DG, Hamblin TJ, Stevenson FK. Typical Waldenström macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood. 2002;100(4):1505-7.
4. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346(8):564-9.
5. Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005;23(21):4662-8.
6. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111(7):3388-94.
7. Bida JP, Kyle RA, Therneau TM, Melton LJ 3rd, Plevak MF, Larson DR, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009;84(8):685-93.
8. Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85(6):383-90.
9. Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci. 1993;114(2):193-9
10. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol. 1991;30(1):54-61.
11. Yeung KB, Thomas PK, King RH, Waddy H, Will RG, Hughes RA, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991;238(7):383-91.
12. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(6):573-89.
13. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol. 1995;37 (Suppl 1):S32-42.
14. Solders G, Nennesmo I, Ernerudh J, Cruz M, Vrethem M. Lymphocytes in sural nerve biopsies from patients with plasma cell dyscrasia and polyneuropathy. J Peripher Nerv Syst. 1999;4(2):91-8.
15. Favereaux A, Lagueny A, Vital A, Schmitter JM, Chaignepain S, Ferrer X, et al. Serum IgG antibodies to P0 dimer and 35 kDa P0 related protein in neuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 2003;74(9): 1262-6.
16. Ekerfelt C, Ernerudh J, Vrethem M. Th1like responses to peptides from peripheral nerve myelin proteins in patients with polyneuropathy associated with monoclonal gammopathy. Clin Exp Immunol. 1997;108(3):516-22.
17. Hammer JA, O'Shannessy DJ, De Leon M, Gould R, Zand D, Daune G, Quarles RH, et al. Immunoreactivity of PMP-22, P0, and other 19 to 28 kDa glycoproteins in peripheral nerve myelin of mammals and fish with HNK1 and related antibodies. J Neurosci Res. 1993;35(5):546-58.
18. Murray N, Page N, Steck AJ. The human anti-myelin-associated glycoprotein IgM system. Ann Neurol. 1986;19(5):473-8.
19. Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol. 1988;3(4):301-32.
20. McGarry RC, Helfand SL, Quarles RH, Roder JC. Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature. 1983;306(5941):376-8.
21. Quarles RH. Myelin-associated glycoprotein (MAG): past, present and beyond. J Neurochem. 2007;100(6):1431-48.
22. Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol. 2008;26(2):55-65.
23. Ilyas AA, Quarles RH, Brady RO. The human peripheral nerve ganglioside. Biochem Biophys Res Commun. 1984; 122(3):1206-11.
24. Chou DK, Ilyas AA, Evans JE, Costello C, Quarles RH, Jungalwala FB. Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy. J Biol Chem. 1986;261(25):11717-25.
25. Quarles RH, Weiss MD. Autoantibodies associated with peripheral neuropathy. Muscle Nerve. 1999;22(7):800-22.
26. Suneetha LM, Singh SS, Vani M, Vardhini D, Scollard D, Archelos JJ, et al. Mycobacterium leprae binds to a major human peripheral nerve glycoprotein myelin P zero (P0). Neurochem Res. 2003;28(9):1393-9.
27. Vardhini D, Suneetha S, Ahmed N, Joshi DS, Karuna S, Magee X, et al. Comparative proteomics of the Mycobacterium leprae binding protein myelin P0: its implication in leprosy and other neurodegenerative diseases. Infect Genet Evol. 2004;4(1):21-8.
28. Vrethem M, Dahle C, Ekerfeldt C, Nilsson J, Ekstedt B, Ernerudh J. Abnormalities in T-lymphocyte populations in blood from patients with demyelinating polyneuropathy associated with monoclonal gammopathy. J Neurol Sci. 1994;122(2):171-8.
29. Vrethem M, Skogh T, Ernerudh J, Ekstedt B, Andersen O, Lycke J. Soluble interleukin-2 receptor levels in serum of patients with demyelinating polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 1993;56(6):721-2.
30. Vrethem M, Ernerudh J, Cruz M, Olerup O, Solders G, Ekstedt B, et al. Susceptibility to demyelinating polyneuropathy in plasma cell dyscrasia may be influenced by amino acid position 9 of the HLA-DR beta chain. J Neuroimmunol. 1993;43(1-2):139-44.
31. Latov N, Godfrey M, Thomas Y, Nobile-Orazio E, Spatz L, Abraham J, et al. Neuropathy and anti-myelin-associated glycoprotein IgM M proteins: T cell regulation of M protein secretion in vitro. Ann Neurol. 1985;18(2):182-8.
32. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood. 2005;105(5):2007-15.
33. Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, et al. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006;107(7): 2871-8.
34. Norton WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J Neurochem. 1973;21(4):749-57.
35. Kadlubowski M, Hughes RA, Gregson NA. Experimental allergic neuritis in the Lewis rat: characterization of the activity of peripheral myelin and its major basic protein, P2. Brain Res. 1980;184(2):439-54.
36. Kvarnström M, Sidorova E, Nilsson J, Ekerfelt C, Vrethem M, Söderberg O, et al. Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS). Clin Exp Immunol. 2002;127(2):255-62.
37. Nichols TC, Guthridge JM, Karp DR, Molina H, Fletcher DR, Holers VM. Gamma-glutamyl transpeptidase, an ectoenzyme regulator of intracellular redox potential, is a component of TM4 signal transduction complexes. Eur J Immunol. 1998;28(2):4123-9.
38. Sander B, Andersson J, Andersson U. Assessment of cytokines by immunofluorescence and the paraformaldehydesaponin procedure. Immunol Rev. 1991;119:65-93.
39. Jansson A, Ernerudh J, Kvarnström M, Ekerfelt C, Vrethem M. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferonbeta1a or glatiramer acetate compared with untreated patients. Mult Scler. 2003;9(5):440-5.
40. Dayton MA, Knobloch TJ, Benjamin D. Human B cell lines express the interferon gamma gene. Cytokine. 1992;4(6):454-60.
41. Bhaduri-McIntosh S, Rotenberg MJ, Gardner B, Robert M, Miller G. Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood. 2008;111(3): 1334-43.
42. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001;17(12):1236-7.
43. Donnes P, Elofsson A. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics. 2002;3:25.
44. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008;4(4):e1000048.
45. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton KA, et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics. 2005;57(5):304-14.
46. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics. 2007;8:238.
47. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol. 1999;17(6):555-61.
48. Kursula P. Structural properties of proteins specific to the myelin sheath. Amino Acids. 2008;34(2):175-85.
49. Louvet C, Kabre BG, Davini DW, Martinier N, Su MA, DeVoss JJ, et al. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med. 2009;206(3): 507-14.
50. Mikaelsson E, Danesh-Manesh AH, Luppert A, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood. 2005; 105(12):4828-35.
51. Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner CM. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood. 2005;105(12):1566-73.
52. Lyons JA, San M, Happ MP, Cross AH. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol. 1999;29(11):3432-9.
53. Rabinowitz R, Hadar R, Schlesinger M. The appearance of the CD4+CD8+ phenotype on activated T cells: possible role of antigen transfer. Hum Immunol. 1997;55(1):1-10.
54. Lusso P, De Maria A, Malnati M, Lori F, DeRocco SE, Baseler M, Gallo RC. Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. Nature. 1991; 349(6309):533-5.
55. Ortolani C, Forti E, Radin E, Cibin R, Cossarizza A. Cytofluorimetric identification of two populations of double positive (CD4+,CD8+) T lymphocytes in human peripheral blood. Biochem Biophys Res Commun. 1993;191(2):601-9.
56. Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood. 2004;104(2):478-86.
57. Schlesinger I, Rabinowitz R, Brenner T, Abramsky O, Schlesinger M. Changes in lymphocyte subsets in myasthenia gravis: correlation with level of antibodies to acetylcholine receptor and age of patient. Neurology. 1992;42(11):2153-7.
58. Munschauer FE, Stewart C, Jacobs L, Kaba S, Ghorishi Z, Greenberg SJ, Cookfair D, et al. Circulating CD3+ CD4+ CD8+ T lymphocytes in multiple sclerosis. J Clin Immunol. 1993;13(2):113-8.
59. Brouet JC, Mariette X, Gendron MC, Dubreuil ML. Monoclonal IgM from patients with peripheral demyelinating neuropathies cross-react with bacterial polypeptides. Clin Exp Immunol. 1994; 96(3):466-9.
60. Vera J, Fenutria R, Canadas O, et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci USA. 2009;106(5):1506-11.
61. Shapiro L, Doyle JP, Hensley P, Colman DR, Hendrickson WA. Crystal structure of the extracellular domain from P0, the major structural protein of peripheral nerve myelin. Neuron. 1996;17(3):435-49.